Protocol Addendum I8F-MC-GPGE(1)
Pharmac
okinetics, Safety, and Tolerability of a Solution  Formulation of LY3298176 in 
Healthy Subjects  
[STUDY_ID_REMOVED] 
Approval Date: 31-Aug-2018
I8F - MC- GPGE (1 )  C l in ica l  P ro toco lAddendum Page  1
LY32981761 .P ro toco l  Addendum  I8F - MC- GPGE(1 )
Pha rmacok ine t ics ,  Sa fe ty,  and  To le rab i l i ty  o f  a  So lu t ion
Fo rmu la t ion  o f  LY3298176  in  Hea l thy Sub jec ts
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th is  p ro toco l  addendum  is  con f iden t ia l  and  is  
in tended  fo r  the  use  o f  c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  
i ts  subs id ia r ies  and  shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lved  in  the  
c l in ica l  inves t iga t ion  o f  LY3298176,  un less  such  pe rsons  a re  bound  by  a  con f iden t ia l i ty  
ag reemen t  w i th  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies .  Th is  documen t  and  i ts  assoc ia ted  
a t tachmen ts  a re  sub jec t  to  Un i ted  S ta tes  F reedom  o f  In fo rma t ion  Ac t  (FO IA )  Exemp t ion  4 .  
App ro va l  Da te :  31 -Aug -2018  GMTLY3298176
Th i s  addendum  i s  to  be  pe r fo rmed  in  add i t ion  to  a l l  p ro cedu re s  requ i red  b y  p ro to co l  
I8F - MC- GPGEo r  an y  sub sequen t  amendmen t s  to  tha t  p ro to co l .
E l i  L i l l y  and  Compan y
Ind ianapo l i s ,  Ind iana  [LOCATION_003]  [ZIP_CODE]
P ro toco l  Addendum  (1)  E lec t ro n i ca l l y  S igned  and  App ro ved  b y  L i l l y  on  da te  p ro v ided  
be low.
I8F-MC-GPGE(1) Clinical Protocol Addendum Page 2
LY32981762.Table of Contents
Protocol A ddendum I8F- MC-GPGE(1)
Pharmacokinetics, Safety , and Tolerability  of a Solution 
Formulation of LY3298176 in Healthy  Subjects
Section Page
1. Protocol  Addendum I8F -MC-GPGE(1) Pharmacokinet ics, Safet y, 
and Tol erabili ty of a Sol ution Form ulation of LY3298176 in Healt hy 
Subjects .............................................................................................................................. [ADDRESS_944956] ives and Endpo ints............................................................................................... 9
4.3. Overall Design ............................................................................................................... 9
4.4. Number of Participants .................................................................................................10
4.5. Scientific Rationale for Study  Design ........................................................................... 10
4.6. Justification o f Dose and Route of Administration ........................................................ 10
4.7. Inclusio n and Exclusio n Cri teria................................................................................... 10
4.8. Treatment Administered ............................................................................................... 10
4.9. Blinding ....................................................................................................................... 11
4.10. Dose Mod ificat ion........................................................................................................ 11
I8F-MC-GPGE(1) Clinical Protocol Addendum Page [ADDRESS_944957] of Tables
Table Page
Table GPGE(1).4.1. Object ives and Endpo ints...................................................................... 9
I8F - MC- GPGE (1 )  C l in ica l  P ro toco lAddendum Page  [ADDRESS_944958] e t e d  i n  a l l  3  e x i s t i n g  p a r t s  (A ,  B ,  a n d  C )  o f  S tudy I8F - MC- GPGE  
(GPGE ) .   Th is  p ro to co l  add endum  add s  a  fou r th  p a r t ,  D .
P a r t  D  w i l l  e v a l u a t e  t h e  p h a rm a c o k i n e t i c s  (PK )  o f  LY 3 2 9 8 1 7 6  f ol l o w i n g  b ol u s  i n t r av enou s  ( IV )
a dm i n i s t r a t i o n .   Th i s  i n f o rm a t i o n  w i l l  e n a b l e  t h e  s t u d y  t e am to  c a l c u l a t e  t h e  a b s o l u t e  
b i o a v a i l a b i l i ty  o f  LY 3 2 9 8 1 7 6  f o l l o w i n g  sub cu t an eou s  ( SC)a dm i n i s t r a t i o n  ( u s i n g  p r i o r  SC  PK  
d a t a  f rom  P h a s e1S tudy I8F - MC- GPGA[GPGA ] ) .   S u b c u t a n e o u sa dm i n i s t r a t i o n  i s  t h e  i n t e n d e d  
r o u t e  f o r  t h i s  d r u g  a s  a  t h e r a p e u t i c .
P a r t  D  w i l l  m im i cth e  d e s i g n  and  s tudy  popu l a t i o n  o f  P a r t  B .   P a r t  B  w a sa nIV  a rm ,  w i th  0 .5  m g  
LY 3 2 9 8 1 7 6a dm i n i s t e r e d  a s  i n f u s i o n  v i a  p um po v e r  1 0  m i n u t e s .   E v a l u a ti o n  o f  IV  PK  in  P a r t  B  
l e d  t o  i n c o n c l u s i v e  r e s u l t s :   LY 3 2 9 8 1 7 6  e x p o s u r ef o l l ow i n g  0 .5 - m g  IV  i n f u s i o n  w a s  low e r  th an  
exp e c t ed  i n  a l l  8  sub j e c t s .E x p e c t a t i o n  w a sb a s e d  o n  p r i o r  u n d e r s t a n d i n g  of  LY 3 2 9 8 1 7 6  PK ,  
 
 
 T h e  r e a s o n  f o r  t h e  l ow e r - th a n - e x p e c t e d  e x p o s u r e  
i s  c u r r e n t l y  u n c l e a r  d e s p i t e  a  c om p l e t e di n v e s t i g a t ion .
T h e  a im  o f  P a r t  D  i s  t o  p r o v i d e  IV  PK  d a t a  to  e s t im a t eth e  a b s o l u t e  b i o a v a i l a b i l i t yo f  
LY 3 2 9 8 1 7 6.P a r t  D  w i l l  u s e0 .5  m gLY3298176  lyo p h i l i z e d  d r u g  p r o d u c t  (GPGE  p r o t o c o l  
S e c t ion  7 .1 .1 ) .   Th i s  con t r a s t s  w i th  P a r t  B ,  wh i ch  u s ed  LY3298176  so l u t i on  d rug  p rodu c t  (GPGE  
p ro to co l  S e c t i on  7 .1 .2 ) .
I8F-MC-GPGE(1) Clinical Protocol Addendum Page 5
LY32981764.Protocol A dditions
4.1. Study Schedule
I8F-MC-GPGE(1) Clinical Protocol Addendum Page 6
LY3298176Study Schedule Protocol I8F -MC -GPGE, Part D
Procedure
(Part D)Screening Treatment ETComments
Days -28 to -2 -1 1 2 3 4 5 6 7 8 15 35 - 37 ≥[ADDRESS_944959] 
Discharge from 
CRUXSubjects may stay 
longer according to 
investigator ’s
discretion
Outpatient Visit X X X X X X X X X
Investigational 
Product 
AdministrationXStudy  drug will be 
administered after an 
overnight fast of at 
least 8 hours. Study 
drug will be 
administered through
bolus IV infusion
Medical History X
Height X
Weight X X X X
Vital Signs 
(BP/PR/T) 
(supi[INVESTIGATOR_050]) (hours)X X P 24h 48h X X X XTime points may be 
added if warranted 
and agreed upon 
between Lilly and the 
investigator
Clinical 
Laboratory 
TestsX X X X X XRequires an [ADDRESS_944960]. See GPGE 
protocol Appendix 2 
for details.
Adverse Event X X X X X X X X X X X X X
I8F-MC-GPGE(1) Clinical Protocol Addendum Page 7
LY3298176Procedure
(Part D)Screening Treatment ETComments
Days -28 to -2 -1 1 2 3 4 5 6 7 8 15 35 - 37 ≥[ADDRESS_944961] will be 
performed at Day -1 
and at ET/Follow -up.
Physical 
Exam inationX X X X XAfter screening, 
medical assessment is 
performed only to 
include medical 
review and targeted 
examination, as 
appropriate.
I8F-MC-GPGE(1) Clinical Protocol Addendum Page 8
LY3298176Procedure
(Part D)Screening Treatment ETComments
Days -28 to -2 -1 1 2 3 4 5 6 7 8 15 35 - 37 ≥[ADDRESS_944962] 5 minutes before 
ECG collection and 
remain supi[INVESTIGATOR_696454].
Genetic Sample PSingle sample for 
pharmacogenetic 
analysis taken prior to 
dosing on Day 1.
Immunogenicity 
SamplesP X X X XAll samples for 
immunogenicity 
should be taken 
predose and follow 
up.  Time -matched 
PK sample should be 
collected at each time 
point.
Abbreviations:  BP = blood pressure; CRU = clinical research unit; ECG = electrocardiogram; ET = early  termination; hr = hour(s); IV =intravenous(ly); 
min=minute(s); P= Predose; PK =pharmacokinetic(s) ; PR = pulse rate; T= Temperature
Note:  If multiple procedures take place at the same time point, the following order of the procedures should be used:  ECG, vital si gns, and venipuncture.
I8F-MC-GPGE(1) Clinical Protocol Addendum Page 9
LY32981764.2. Objectives and Endpoints
Table GPGE (1).4.1shows the object ives and endpoints of Part D of the study .
Table GPGE (1).4.1. Objectives and Endpoints
Objectives Endpoints
Part D: 
Primary:  To evaluate the PK of a single 
bolus IV dose of LY3298176 , lyophilized 
formulation, in healthy subjects.
Secondary:  To investigate the safety and 
tolerability of LY3298176, administered to 
healthy  subjects via bolus IV.PK parameters, including AUC 
AEs
Abbreviations:  AE = adverse event; AUC = area under the concentration versus time curve; IV = intravenous(ly); 
PK = pharmacokinetic(s).
4.3. Overall Design
Study  GPGE is a single -center, Phase [ADDRESS_944963] will provide informe d consent for study  parti cipat ion,and will undergo a 
screening examinat ion within 28 days prior to enrollment .
Subjects will be admitted to the clinical research unit ( CRU )on Day  -1. On the morning of 
Day 1, following an overnight fast of at least 8 hou rs, 2 subjects will receive a single bolus IV
dose of 0.5 m g LY3298176 .  This dose is expected to be safe while also providing plasma 
concentrations that can be adequately  measured over the course of the sampling time period to 
enable adequate characterizat ion of the PK profile.
If the dose of 0.5 mg is found to be safe and well tolerated, then 6more 
subjects will be dosed.
If the dose is not tolerated due to extensive gastrointestinal events, a l ower 
dose of 0.25 mg may be administered to an a dditional 8subjects. 
Plasma s amples will be collected multiple times, including predose and up to 336 hours 
postdose ,to measure LY3298176 concentrati ons.  
At a minimum, subjects will remain in the CRU for 4days.  The investigator (or qualified 
designe e) will  review all  available inpat ient safet y data before discharging subjects from the 
CRU on the morning of Day 4, provi ded that the subjects are deemed medically  fit.  Subj ects 
may be required to remain in the CRU longer than Day 4, at the invest igator’ s discret ion.
Each subject will be required to return to the CRU for a fo llow-up visit at least 35days after the 
LY3298176 dose.  In addit ion, subjects will need to attend a study  visit on D ay ≥70 for an 
antidrug ant ibody  follow
-up sample.
I8F - MC- GPGE (1 )  C l in ica l  P ro toco lAddendum Page  10
LY32981764 .4 .Numbe r  o f  Pa rt ic ipan ts
P a r t  D :  A p p r o x im a t e l y  [ADDRESS_944964] e t e  t h i s  p a r t
o f  th e  s tudy .
4 .5 .Sc ien t i f ic  Ra t iona le  fo r  Study  Des ign
S im i l a rlytoo th e r  p a r t s  o f  S tudy  GPGE ,  ap o p u l a ti o n  o f  h e a l t h y  s u b j e c t s  w i l l  b e  e n r o l l e df o r  P a r t  
D  b e c a u s e  i t  i s  l i k e l yth e r e  w i l l  b e  l e s sphy s i o l og i c  v a r i ab i l i ty th an  in  a  p a t i en t  popu l a t i on .   Th i s  
i s  d u e  t o  t h e  a b s e n c e  o f  d i s e a s e  s t a t e s  t h a t  m a y  a f f e c t  m u l t i p l e  o r g a n  s y s t em s ,  a n d  th e  ab s en c e  o f  
o th e r  con found ing  f a c to r ss u c h  a s  c o n c om i t a n t  m ed i c a t i o n s .
P a r t  Dw i l l  i n v e s t i g a t e  t h e  PK  o f  LY 3 2 9 8 1 7 6  f o l l o w i n g  a dm i n i s t r a t i o n  v i a  a  s i n g l e  IV  d o s e
a dm i n i s t e r e d  a s  a  b o l u s .
S a fe t y  and  to l e r a b i l i t y  o f  LY 3 2 9 8 1 7 6  w e r e  e s t a b l i s h e d  b y  d a t a  f r om  S tudy GPGA .   
As a f e t y  r e v i eww i l l b e  p e r fo rm e da f t e r  d o s i n g  t h e  f i r s t  2  s u b j e c t s  t o  r e v i ew  s a f e t y  a n d  
to l e r a b i l i t yf o l l o w i n g  d i s c h a r g e  f r om  th e  CRU  on  D ay  4o f  th e  s tudy ,  a n d  t o  c h e c k  i f  t h e r e  i s  a  
n e e d  f o r  d o s e  a d j u s tm en t p r i o r  to  do s ing  th e  r em ai n i n gs u b j e c t s .
4 .6 .Jus t i f ica t iono f  Dose  and  Rou te  o f  Adm in is t ra t ion
A  d o s e  o f  0 . 5  m g  LY 3 2 9 8 1 7 6  ( a dm i n i s t e r e d  v i a  b o l u s  IV )  i s  c h o s e n  b e c a u s e  t h i s  d o s e  i s  
exp e c t ed  to  l e a d  to  m e a s u r e a b l e  PK  p r o f i l e ,  s in c e  PK  w a s  qu an t i f i a b l e  f o l l o w ing  a  0 .5- m g  IV  
1 0 -m i n u t e  i n f u s i on  do s e  in  P a r t  B  o f  th e  s tudy .P r e l im i n a r y  d a t a  from  P a r t  B  ind i c a t e  th a t  
a dm in i s t r a t i on  o f  LY 3 2 9 8 1 7 6v i a  i n f u s i o n  pum p  w a s  w e l l  to l e r a t ed  by  [CONTACT_3433] e  8  sub j e c t s ,  w i th  n o
a d v e r s e  e v e n t s  b e i n g  r e p o r t e d .
T h e  IV  b o l u s  r o u t e  i n  P a r t  D  i s  e x p e c t e d  t o  p r o v i d e  d a t a  t o  e s t im a t eth ea b s o l u t e  b i o a v a i l a b i l i t y
o f  LY 3 2 9 8 1 7 6 .   Ph a rm a c o k i n e ti ce x p o s u r e  f o l l o w i n g  IV  i n f u s i on  o f  a  0 .5 -m g  d o s e  i n  P a r t  B  w a s  
l o w e r  t h a n  a n ti c i p a t e d ,  i n  a l l  8  s u b j e c t s  d o s e d  
 
4 .7 .Inc lus ion  and  Exc lus ion  C r i te r ia
T h e r e  a r e  n o  a d d i ti o n a l  i n c l u s i o n  o r  e x c l u s i on  c r i t e r i a ,  o r  o th e r  s tudy  popu l a t i o nr equ i r em en t s ,
f o r  P a r t  D  o f  t h es tudy .
4 .8 .T rea tmen t  Adm in is te redCC I
LY 3 2 9 8 1 7 6  l y o p h i l i z e d  f o rm u l a ti o n  w i l l  b e  u s e d  i n  P a r t  D .   S e e  GPGE  p r o t o c o l  S e c t i o n  7 . 1 .1  
f o r  d e t a i l s .
N o  r a n d om i z a t i o n  i s  r e q u i r e d  f o r  P a r t  D .   A  s i n g l e ,  0 .5 - m g  b ol u s  IVd o s e  o f  LY 3 2 9 8 1 7 6w i l l  b e  
a dm i n i s t e r e d  i n  t h e  m o r n i n g  f o l l o w ing  an  8- h o u r ,  o v e r n i g h t  f a s t .T h ea c t u a l  t im e  o f  d o s e  
a dm i n i s t r a t i o n  w i l l  b e  r e c o r d e d  i n  t h e  s u b j e c t ’ se l e c t ro n i c  c a s e  r e p o r t  f o rm .
I8F-MC-GPGE(1) Clinical Protocol Addendum Page [ADDRESS_944965] 2 subjects, to the extent that treatm ent wi th antiemetics and IV
fluidsis required, a reduced dose (0.25 mg) may be administered to the next 8 subjects planned 
in this part.  If the re are no safet y concerns, then the sam e planned dose of 0.5 mg will be 
administered to the next 6 subjec ts enrolled in this part. 
[COMPANY_003]Leo Document ID = 09836199-1f2f-4c11-a490-d47c3459306a
Approver: 
Approval Date & Time: 30-Aug-2018 13:30:45 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 31-Aug-2018 04:02:11 GMT
Signature [CONTACT_32869]: Approved[COMPANY_003]